Tumor necrosis factor (tnf) inhibitor and method for obtaining the same
CA 2021369 A1 · Owner: Synergen, Inc. · Inventors: King, Michael W.; Vanderslice, Rebecca W.; Brewer, Michael T.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
At least two substantially purified tumor necrosis factor (TNF) inhibitors are disclosed which are glycoproteins that are active against TNF. The isolation of 30kDa and 40KDa TNF inhibitors from urine is disclosed. The deglycosylated form of the 30kDa TNF inhibitor and 40kDa TNF inhibitor are described as being active against TNF. The 40kDa TNF inhibitor is active against both TNF alpha and TNF beta. The amino acid sequence of the 30kDa TNF inhibitor and the 40kDa TNF inhibitor are disclosed. Methods for isolating the TNF inhibitors from human U937 cell medium and producing the proteins by recombinant-DNA methods are also described. synergen\newdoc.cipp
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 17, 1990. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended July 17, 2010.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 17, 2012.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.